Aerosol Delivery of SARS-CoV-2 Human Monoclonal Antibodies in Macaques Limits Viral Replication and Lung Pathology

Passively administered monoclonal antibodies (mAbs) given before or after viral infection can prevent or blunt disease. Here, we examine the efficacy of aerosol mAb delivery to prevent infection and disease in rhesus macaques inoculated with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant via intranasal and intratracheal routes. SARS-CoV-2 human mAbs or a human mAb directed to respiratory syncytial virus (RSV) are nebulized and delivered using positive airflow via facemask to sedated macaques pre- and post-infection. Nebulized human mAbs are detectable in nasal, oropharyngeal, and bronchoalveolar lavage (BAL) samples. SARS-CoV-2 mAb treatment significantly reduces levels of SARS-CoV-2 viral RNA and infectious virus in the upper and lower respiratory tracts relative to controls. Reductions in lung and BAL virus levels correspond to reduced BAL inflammatory cytokines and lung pathology. Aerosolized antibody therapy for SARS-CoV-2 could be effective for reducing viral burden and limiting disease severity.

Citing Articles

Effect of obesity on the acute response to SARS-CoV-2 infection and development of post-acute sequelae of COVID-19 (PASC) in nonhuman primates.

Sauter K, Webb G, Bader L, Kreklywich C, Takahashi D, Zaro C bioRxiv. 2025; .

PMID: 40027795 PMC: 11870618. DOI: 10.1101/2025.02.18.638792.

Fc-binding nanodisc restores antiviral efficacy of antibodies with reduced neutralizing effects against evolving SARS-CoV-2 variants.

Hwang J, Choi S, Kim B, Son S, Yoon J, Kim K J Nanobiotechnology. 2025; 23(1):44.

PMID: 39856746 PMC: 11761773. DOI: 10.1186/s12951-025-03100-y.

Potent neutralization by a RBD antibody with broad specificity for SARS-CoV-2 JN.1 and other variants.

Piepenbrink M, Khalil A, Chang A, Mostafa A, Basu M, Sarkar S Npj Viruses. 2024; 2(1):55.

PMID: 39553825 PMC: 11564104. DOI: 10.1038/s44298-024-00063-z.

Impact of mAb-FcRn affinity on IgG transcytosis across human well-differentiated airway epithelium.

Togami K, Wolf W, Olson L, Card M, Shen L, Schaefer A Front Immunol. 2024; 15:1371156.

PMID: 39351230 PMC: 11439726. DOI: 10.3389/fimmu.2024.1371156.

A Biparatopic Intrabody Renders Vero Cells Impervious to Ricin Intoxication.

Czajka T, Vance D, Song R, Mantis N bioRxiv. 2024; .

PMID: 39005371 PMC: 11244990. DOI: 10.1101/2024.07.02.601761.

References

McCallum M, Bassi J, De Marco A, Chen A, Walls A, di Iulio J . SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. Science. 2021; 373(6555):648-654. PMC: 9835956. DOI: 10.1126/science.abi7994. View

Leyva-Grado V, Tan G, Leon P, Yondola M, Palese P . Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies. Antimicrob Agents Chemother. 2015; 59(7):4162-72. PMC: 4468714. DOI: 10.1128/AAC.00290-15. View

Wibmer C, Ayres F, Hermanus T, Madzivhandila M, Kgagudi P, Oosthuysen B . SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med. 2021; 27(4):622-625. DOI: 10.1038/s41591-021-01285-x. View

Loo Y, McTamney P, Arends R, Abram M, Aksyuk A, Diallo S . The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans. Sci Transl Med. 2022; 14(635):eabl8124. PMC: 8939769. DOI: 10.1126/scitranslmed.abl8124. View

Jia J, Yin Z, Zhang X, Li H, Meng D, Liu Q . Feasibility Studies of Nebulized SARS-CoV-2 Neutralizing Antibody in Mice and Cynomolgus Monkeys. Pharm Res. 2022; 39(9):2191-2201. PMC: 9322739. DOI: 10.1007/s11095-022-03340-9. View

Van Rompay K, Olstad K, Sammak R, Dutra J, Watanabe J, Usachenko J . Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques. PLoS Pathog. 2021; 17(7):e1009688. PMC: 8284825. DOI: 10.1371/journal.ppat.1009688. View

Wen X, Mousa J, Bates J, Lamb R, Crowe Jr J, Jardetzky T . Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus. Nat Microbiol. 2017; 2:16272. PMC: 5308794. DOI: 10.1038/nmicrobiol.2016.272. View

Peluso M, Anglin K, Durstenfeld M, Martin J, Kelly J, Hsue P . Effect of Oral Nirmatrelvir on Long COVID Symptoms: 4 Cases and Rationale for Systematic Studies. Pathog Immun. 2022; 7(1):95-103. PMC: 9254867. DOI: 10.20411/pai.v7i1.518. View

Wendisch D, Dietrich O, Mari T, von Stillfried S, Ibarra I, Mittermaier M . SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis. Cell. 2021; 184(26):6243-6261.e27. PMC: 8626230. DOI: 10.1016/j.cell.2021.11.033. View

10.

Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S . SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181(2):271-280.e8. PMC: 7102627. DOI: 10.1016/j.cell.2020.02.052. View

11.

Levin M, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A . Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19. N Engl J Med. 2022; 386(23):2188-2200. PMC: 9069994. DOI: 10.1056/NEJMoa2116620. View

12.

Hewitt J, Lutz C, Florence W, Pitt M, Rao S, Rappaport J . ACTIVating Resources for the COVID-19 Pandemic: In Vivo Models for Vaccines and Therapeutics. Cell Host Microbe. 2020; 28(5):646-659. PMC: 7528903. DOI: 10.1016/j.chom.2020.09.016. View

13.

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

14.

Alsoussi W, Turner J, Case J, Zhao H, Schmitz A, Zhou J . A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. J Immunol. 2020; 205(4):915-922. PMC: 7566074. DOI: 10.4049/jimmunol.2000583. View

15.

Vonarburg C, Loetscher M, Spycher M, Kropf A, Illi M, Salmon S . Topical application of nebulized human IgG, IgA and IgAM in the lungs of rats and non-human primates. Respir Res. 2019; 20(1):99. PMC: 6532128. DOI: 10.1186/s12931-019-1057-3. View

16.

Parray H, Shukla S, Perween R, Khatri R, Shrivastava T, Singh V . Inhalation monoclonal antibody therapy: a new way to treat and manage respiratory infections. Appl Microbiol Biotechnol. 2021; 105(16-17):6315-6332. PMC: 8380517. DOI: 10.1007/s00253-021-11488-4. View

17.

Corti D, Purcell L, Snell G, Veesler D . Tackling COVID-19 with neutralizing monoclonal antibodies. Cell. 2021; 184(12):3086-3108. PMC: 8152891. DOI: 10.1016/j.cell.2021.05.005. View

18.

Munoz-Fontela C, Dowling W, Funnell S, Gsell P, Riveros-Balta A, Albrecht R . Animal models for COVID-19. Nature. 2020; 586(7830):509-515. PMC: 8136862. DOI: 10.1038/s41586-020-2787-6. View

19.

Schultze J, Aschenbrenner A . COVID-19 and the human innate immune system. Cell. 2021; 184(7):1671-1692. PMC: 7885626. DOI: 10.1016/j.cell.2021.02.029. View

20.

Freed N, Vlkova M, Faisal M, Silander O . Rapid and inexpensive whole-genome sequencing of SARS-CoV-2 using 1200 bp tiled amplicons and Oxford Nanopore Rapid Barcoding. Biol Methods Protoc. 2020; 5(1):bpaa014. PMC: 7454405. DOI: 10.1093/biomethods/bpaa014. View